Media headlines about Charles River Laboratories Intl. (NYSE:CRL) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Charles River Laboratories Intl. earned a news sentiment score of 0.08 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 47.9103665648042 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Charles River Laboratories International Inc.: Charles River Laboratories Acquires KWS BioTest (twst.com)
- Charles River Lab Acquires KWS BioTest – Quick Facts (markets.businessinsider.com)
- BRIEF-Charles River Laboratories Says New Tax Legislation Expected To Be Effectively Neutral To Co’s GAAP, Non-GAAP EPS In 2018 (reuters.com)
- Carl Data Solutions Announces Completion of Rights Offering (finance.yahoo.com)
Several research firms recently weighed in on CRL. Jefferies Group raised their target price on shares of Charles River Laboratories Intl. from $120.00 to $130.00 and gave the company a “buy” rating in a research note on Monday, October 9th. Bank of America cut their target price on shares of Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, November 10th. Zacks Investment Research raised shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 target price for the company in a research note on Tuesday, October 24th. Robert W. Baird set a $117.00 target price on shares of Charles River Laboratories Intl. and gave the company a “buy” rating in a research note on Monday, November 13th. Finally, Argus began coverage on shares of Charles River Laboratories Intl. in a research note on Wednesday, December 13th. They set a “buy” rating and a $120.00 target price for the company. Six analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $112.36.
Charles River Laboratories Intl. (CRL) opened at $105.34 on Friday. The firm has a market cap of $4,990.00, a price-to-earnings ratio of 25.76, a P/E/G ratio of 1.64 and a beta of 0.88. Charles River Laboratories Intl. has a 52 week low of $77.61 and a 52 week high of $119.05. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.62 and a current ratio of 1.88.
Charles River Laboratories Intl. (NYSE:CRL) last issued its quarterly earnings data on Thursday, November 9th. The medical research company reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. Charles River Laboratories Intl. had a net margin of 10.72% and a return on equity of 26.58%. The business had revenue of $464.23 million during the quarter, compared to analysts’ expectations of $458.93 million. During the same period last year, the company posted $1.18 EPS. The business’s revenue was up 9.0% on a year-over-year basis. equities analysts predict that Charles River Laboratories Intl. will post 5.14 EPS for the current fiscal year.
In other Charles River Laboratories Intl. news, Chairman James C. Foster sold 4,967 shares of Charles River Laboratories Intl. stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $109.44, for a total value of $543,588.48. Following the completion of the transaction, the chairman now directly owns 329,928 shares of the company’s stock, valued at approximately $36,107,320.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Ross Smith sold 5,486 shares of Charles River Laboratories Intl. stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $109.53, for a total transaction of $600,881.58. The disclosure for this sale can be found here. Over the last three months, insiders acquired 10,500 shares of company stock valued at $2,885 and sold 1,064,673 shares valued at $2,876,056. Company insiders own 2.20% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://ledgergazette.com/2018/01/13/charles-river-laboratories-intl-crl-earning-somewhat-favorable-news-coverage-analysis-finds.html.
About Charles River Laboratories Intl.
Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.
Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.